The Vel blood group system: a review by Storry, Jill R. & Peyrard, Thierry
56 IMMUNOHEMATOLOGY, Volume 33, Number 2, 2017
The Vel blood group system: a review
J.R. Storry and T. Peyrard
Revie w
The blood group antigen Vel has been one of immunohematology’s 
greatest enigmas: the variation in antigen strength from one 
individual to another, the property of anti-Vel to readily hemolyze 
Vel+ red blood cells (RBCs), and the difficulty to screen for 
sufficient numbers of Vel– blood donors had made Vel a tough 
nut to crack. In 2013, a small, previously unknown protein called 
small integral membrane protein 1 (SMIM1) was identified on 
the RBC by three independent research groups using different 
approaches, and all three groups demonstrated that Vel– RBCs 
lacked SMIM1. This discovery correlated with homozygosity 
for deletion c.64_60del in SMIM1 and meant that for the first 
time there was a universal method to screen for Vel– blood 
donors. This finding was not the whole answer, however, and an 
explanation behind the variability in antigen strength was later 
shown to be due to polymorphism in SMIM1 intron 2, a region 
that is responsible for gene transcription. Clinically, anti-Vel is 
important and has caused severe transfusion reactions, although 
hemolytic disease of the fetus and newborn caused by anti-Vel 
is uncommon. However, while screening for Vel– blood donors 
has become easier, the function of SMIM1 is still unknown, and 
despite its well-conserved sequence across the animal kingdom, 
the enigma continues. Immunohematology 2017;33:56–59.
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The first report of anti-Vel was published in the French 
journal Revue d’Hematologie by Sussman and Miller in 1952 
and concerned a patient in New York who received 2 units 
of crossmatch-compatible blood.1 As reviewed by Sussman 
some 10 years later, the original proband was a patient with 
colon cancer who suffered a severe and immediate transfusion 
reaction following the second transfusion in a 3-day period. 
Although she had a history of uneventful pregnancies and 
transfusions prior to this occasion, her serum several days 
post-transfusion was strongly incompatible with the second 
unit transfused, although it remained compatible with the first 
unit.2 Subsequent screening of 10,000 donors with the patient’s 
serum in New York revealed only 4 compatible units in addition 
to the serendipitous compatible unit. This antibody displayed 
a clear dosage effect reacting with a titer of 64–128 with red 
blood cells (RBCs) from one group of individuals and more 
weakly (titer of 8–16) with RBCs from a second group that 
included the (presumed heterozygous) children of the patient.2
A second example of anti-Vel followed 3 years later, 
described by Levine et al., in a 67-year-old woman diagnosed 
with diverticulitis of the colon.3 She had received 1 unit of 
crossmatch-compatible blood 6 years previously following 
surgery for removal of an ovarian cyst, and she had a history 
of two pregnancies. At the time of the report, the patient’s 
serum contained a hemolytic antibody that was shown to 
be compatible only with the RBCs of the original proband 
and incompatible with over 1000 donors tested. Hemolytic 
reactivity has been a hallmark of anti-Vel, and Sussman had 
reported earlier that anti-Vel from 12 of 19 patients hemolyzed 
RBCs in vitro.2
In a study of Vel– families in northern Sweden, a 
disproportionate number of Vel– individuals were found 
to demonstrate a P2 phenotype,4 although this apparent 
association has been subsequently disproved.5 An association 
between Vel and Gerbich antigens was first demonstrated in 
a patient with anti-Ge.6 The patient’s RBCs were nonreactive 
with some Vel antibodies. Subsequent testing of 14 Vel 
antibodies with eight examples of Ge:–2,–3,4 RBCs revealed 
three antibodies that failed to react with at least four of the 
RBC samples, and two other antibodies that were nonreactive 
with some. Subsequent elegant flow cytometry studies by 
Haer-Wigman et al.7 showed that there was no differential 
expression of glycophorin C (GPC) on Vel– RBCs when 
compared with that on Vel+ RBCs, but that variation could be 
attributed to the rs1175550 single-nucleotide polymorphism 
known to influence Vel antigen expression (see the Molecular 
Basis section).
Lastly, serological evidence suggested that the high-
prevalence antigen ABTI was related to Vel; in the original 
report of ABTI, it was noted that of eight Vel– samples, six 
reacted only weakly with anti-ABTI, and one did not react 
at all.8 In a second report, two new examples of anti-ABTI 
reacted only weakly with several examples of Vel– RBCs, 
confirming a serological connection, at least.9 Based on these 
reports, an International Society of Blood Transfusion (ISBT) 
collection, 200212, was created to accommodate Vel and 
ABTI. ABTI was returned to the 901 series (901015), following 
the identification of SMIM1 as the gene responsible for the 
Vel– phenotype. Indeed, SMIM1 sequence analysis of ABTI– 
individuals did not reveal a mutation that could account for the 
phenotype, and thus the ABTI blood group antigen remains 
uncharacterized.10
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Although Vel has been detected on fetal RBCs from 12 
weeks of gestation, it is expressed less strongly on cord cells 
than on adult cells.11,12 Vel is not detected on lymphocytes, 
granulocytes, or monocytes.13
The nomenclature for Vel is presented in Table 1.
Genetics/Inheritance
The Vel blood group antigen is inherited as a dominant 
trait. It is dependent on the expression of small integral 
membrane protein 1 (SMIM1), encoded by SMIM1, which 
is located on chromosome 1 at 1p36. The prevalence of the 
Vel– phenotype in Europe varies from ~1 in 5000 in southern 
regions to ~1 in 1200 in Sweden.7,14,15 Its prevalence is much 
lower in people of African and Asian descent, where the 
prevalence of the mutated allele has been observed as 0.56 
percent and 0.6 percent of these respective populations.7
Molecular Basis
Although Vel has been well defined serologically and there 
is a large set of observational data concerning the antibodies 
produced in response to Vel, nothing is known about the 
structure that carries Vel. The molecular basis of the Vel– 
phenotype was identified as a deletion of 17 bp in the coding 
region of the SMIM1 gene, SMIM1 c.64_80del.14,16,17 This 
deletion has been shown to be the primary molecular basis 
for the Vel– phenotype in all populations. Expression of Vel 
can be very weak, however, and varies considerably from the 
RBCs of one individual 
to another. Missense 
mutations at nucleotide 
position 152 (c.152T>A 
or c.152T>G; p.Met51Lys 
and p.Met51Arg, re-
spectively) have been 
identified in individuals 
who type as Vel+w,16,17 
and expression studies 
in an HEK293T cell line using constructs with these two 
mutations demonstrated that Vel was markedly diminished 
in cells transfected with the SMIM1 c.152A construct and not 
expressed at all by HEK293T cells transfected with SMIM1 
c.152G.7 Table 2 lists the molecular changes in the coding 
region of SMIM1 associated with the Vel antigen.
The identification of the molecular basis underlying the 
Vel– phenotype has enabled the development of polymerase 
chain reaction–based screening. This strategy has been 
successfully used to identify new Vel– donors in several 
laboratories.7,14,15,18
There are other noncoding polymorphisms in the 
regulatory region in SMIM1 intron 2 that have also been shown 
to correlate with Vel antigen expression. The rs1175550 was 
first identified in 2012 in the investigation of genes that affect 
RBC morphology and function and was shown to be correlated 
with a lower mean corpuscle hemoglobin count (MCHC).19 
This single nucleotide polymorphism has been extensively 
investigated, and the more common allele, rs1175550A, is 
associated with weak expression of Vel. The less frequent 
allele, rs1175550G, is associated with stronger expression 
that is zygosity-dependent.7,20 The mechanism for this is not 
entirely understood, although the change of A>G disrupts a 
recognition site for the erythroid-specific transcription factor, 
GATA-1. It was first postulated that this GATA-1 site acted as 
a negative regulator for SMIM1, but further evaluation of this 
region has shown that there are other transcription factors 
that play a role—for example, TAL1, which was shown to bind 
preferentially to the rs1175550G allele and to upregulate Vel 
antigen expression.21,22 Another polymorphism, a trinucleotide 
insertion, rs143702418, also correlates with SMIM1 and with 
Vel antigen expression; the less frequent insertion is associated 
with downregulation and thus reduced expression.22
Biochemistry
SMIM1 encodes SMIM1. This protein is a single-pass 
membrane protein of 78 amino acids whose physiological role 
Table 1. Nomenclature of Vel blood group system
Blood group system Vel






Table 2. Alleles of the Vel blood group system recognized by the ISBT†
Phenotype Allele name Nucleotide change in SMIM1 Exon Predicted amino acid change
Vel+ VEL*01
Vel– VEL*−01 c.64_80delAGCCTAGGGGCTGTGTC 3 p.Ser22Glnfs
Vel+w VEL*01W.01 c.152T>A 4 p.Met51Lys
Vel+w/Vel– VEL*01W.02 c.152T>G 4 p.Met51Arg
ISBT = International Society of Blood Transfusion; w = weak.
†Only the polymorphisms in the coding region that have been found to affect antigen expression are shown. For further 
variation in the gene, see www.erythrogene.com and www.ensembl.org.
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and membrane topology remain unclear. Arnaud et al.23 used 
recombinant hybrids of SMIM1 and Flag protein, as well as 
Kell-SMIM1 hybrids, in different orientations to show that 
SMIM1 was a type II membrane protein with an extracellular 
C-terminus. Western blotting experiments following different 
protease treatments of intact RBCs indicated α-chymotrypsin 
sensitivity, however, which suggested that the protein exposed 
the N-terminus extracellularly. 
There is more work to be done! SMIM1 does not appear 
to be glycosylated but is readily phosphorylated in vitro.23 
Phosphoproteomics analysis of human RBCs following 
invasion by Plasmodium falciparum showed that SMIM1 was 
phosphorylated in association with the schizont stage of the 
parasite life cycle,24 and although any role of SMIM1 in parasite 
invasion has not been described, these results are tantalizing. 
It is unknown whether SMIM1 associates with other (glyco)
proteins in the RBC membrane, but it is a very small protein, 
and it would not be atypical for it to form a functional complex.
Antibodies in the System
Anti-Vel is the only antibody in the Vel blood group system. 
Antibodies to Vel are produced after immunization and are 
not naturally occurring. Unlike most antibodies to blood 
group antigens, anti-Vel sera are usually a mixture of IgM and 
IgG, fix complement readily in vitro, and demonstrate a wide 
thermal range of reactivity.25 Blood group antigen-specific IgM 
antibodies that do not readily class-switch to IgG antibodies 
are suggestive of an immune response to carbohydrate 
antigens such as A, B, H, P, and so forth. Unlike anti-Vel, 
however, these antibodies are almost invariably naturally 
occurring. Many Vel antibodies are readily adsorbed by rabbit 
RBCs or red cell stroma, although this is apparently not a 
specific adsorption but more that these reagents preferentially 
adsorb IgM antibodies.26,27 The ability to hemolyze Vel+ RBCs, 
at least in the days when serum was used for testing, has been 
a hallmark of anti-Vel and, in his review, Sussman reported 
that anti-Vel from 12 of 19 patients hemolyzed RBCs in vitro.2
The serological reactivity of anti-Vel with RBCs treated 
with papain, ficin, trypsin, and α-chymotrypsin is greatly 
enhanced, and serum containing anti-Vel will often readily 
hemolyze papain-treated RBCs, for example. Vel antigen is 
also unaffected by neuraminidase treatment.28 The effect of 
200 mmol/L dithiothreitol (DTT) treatment of Vel+ RBCs 
varies, with some anti-Vel recognizing a DTT-sensitive 
antigen, while the majority are unaffected.14,29 Rainer et al.29 
demonstrated that of 11 antibodies tested, one sample was 
completely nonreactive with DTT-treated RBCs, four samples 
showed a decrease in reactivity of greater than or equal to 
1+, and six samples were unaffected by the DTT treatment. 
Additionally, one report described the enhancement of anti-
Vel reactivity following treatment of test RBCs with sodium 
hypochlorite.30
Screening for Vel– blood donors has been hampered by the 
lack of suitable anti-Vel reagent, and blood centers have been 
restricted to limited volumes of the antibody from patients. 
Recently, a human monoclonal anti-Vel was produced by the 
French blood service, thus providing the potential for a long-
awaited serologic screening and typing reagent.31 As of today, 
more than 950,000 blood donations in France have been 
screened for Vel with this monoclonal reagent, and 320 new 
Vel– blood donors were identified (unpublished data, personal 
communication with Michel Hennion, Etablissement Français 
du Sang Nord de France, Lille, France).
Clinical Significance
Anti-Vel is clinically important and has caused transfusion 
reactions ranging from mild to severe.28 In one case in 
which reactivity of an anti-Vel was attributed to a clinically 
insignificant cold-reactive antibody, 2 units of Vel+ blood 
were transfused, and the patient suffered a severe transfusion 
reaction and died 8 hours later.32 In France, it has been 
estimated that a mean of one severe hemolytic transfusion 
reaction caused by anti-Vel occurred per year between 1995 
and 2009 (mean annual incidence of 1.7 per 108 inhabitants).5 
Hemolytic disease of the fetus and newborn caused by anti-Vel 
has been described but is rare,33,34 possibly due in part to the 
weaker expression of Vel on cord RBCs. Examples of autoanti-
Vel have also been reported. The first described was an IgM 
autoanti-Vel in an untransfused male patient with aplastic 
anemia.35 No shortened survival of 51Cr-labeled Vel+ RBCs was 
demonstrated. In contrast, a young girl with steroid-resistant 
warm autoimmune hemolytic anemia and an associated 
autoanti-Vel suffered a severe transfusion reaction when given 
2 units of Vel+ blood.36 Vel– blood was tolerated well.
In conclusion, the Vel blood group system is a simple 
system consisting of just one antigen to date. Its complexity 
lies in the variation in antigen expression, which in turn makes 
anti-Vel sometimes difficult to identify, as well as the lack of 
availability of Vel– blood donors in most parts of the world. 
Vel is an antibody to be treated with respect because even 
weak antigen expression can have clinical consequences, as 
witnessed with the very first patient.
J.R. Storry and T. Peyrard
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